It has to shift priority from nonessential things to more essential things
The field moved from single GLP-1 receptor agonism, to dual GIP/GLP-1 agonism, and then to adding a third receptor glucagon to capture an energy-expenditure lever on top of appetite and glucose control
Gastrointestinal adverse events nausea, vomiting, diarrhea are fairly common, while pancreatitis and intestinal obstruction are rarer but documented
This is a common tactic: The 1-month option exists, but it is priced to feel not worth it. The 3-month and 6-month options are framed as the smart choice
Both semaglutide and tirzepatide can be compounded with glycine, and the glycine serves the same stabilizing and therapeutic functions in both formulations
For a more detailed breakdown of optimal locations, check our guide on where to inject GLP-1